Tamrisa

Tamrisa is a French pharmaceutical company based in Paris, focused on combating antimicrobial resistance.

Founded around 2023–2024, it is dedicated to developing innovative solutions in line with World Health Organization guidelines. The company aims to create a sustainable response to resistant infections through its development, commercialization, and access strategies. Tamrisa specializes in pharmaceutical development and commercialization for anti-infective therapies. It has built a portfolio of eight long-proven antibiotics that are registered and available in over 40 countries through distribution partners. Additionally, the company is developing TMR010, a novel intravenous drug designed to target infections caused by carbapenem-resistant Enterobacterales.